Aradigm Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported revenues were $1,473,000 against $1,693,000 for the same period a year ago. Loss from operations was $3,809,000 against $2,759,000 for the same period a year ago. Net loss and comprehensive loss was $4,802,000 against $3,678,000 for the same period a year ago. Basic and diluted net loss per common share was $0.32 against $0.25 for the same period a year ago. The increase in net loss resulted primarily from an increase in operating expenses of $800,000 related to the FDA meeting in January and the submission of the MAA to EMA in March for approval of Linhaliq.